Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECAR01 in Refractory Autoimmune Diseases
NCT07052565Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jul 2025
- Primary completion
- Nov 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ECAR01 in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren's syndrome and 1 more, sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Adverse events at 1 year. Started Jul 2025; status: recruiting.
02
Drugs
ECAR01
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)Sjögren's syndromesystemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07052565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052565.